News Sentiment

ORIC sentiment intelligence

Oric Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.85 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.8% over one week, +31.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.8% Price reacting lower
Trend fit Trend inactive 31.2% over four weeks
Fair value 14.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 30
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 6
Market source 6
GlobeNewswire 5
simplywall.st 4
Investing.com 3
Stock Traders Daily 2
Simply Wall Street 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 11
Analyst action 4
Macro sensitivity 1
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Simply Wall Street Direct company coverage

How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC)

ORIC Pharmaceuticals has launched the Himalayas-1 global Phase 3 trial for rinzimetostat with Bayer's NUBEQA in metastatic castration-resistant prostate cancer, enrolling about 600 patients. This trial positions rinzimetostat as a late-stage asset and a major clinical catalyst fo

Tone
Positive 61/100
Event
Market update
Published
15 Jul 2026 11:43
Source
Simply Wall Street
Investing.com Direct company coverage

ORIC Pharmaceuticals initiates phase 3 prostate cancer trial

ORIC Pharmaceuticals (NASDAQ:ORIC) has initiated its Himalayas-1 global Phase 3 trial for metastatic castration-resistant prostate cancer, enrolling approximately 600 patients across 25 countries. The trial will evaluate rinzimetostat in combination with darolutamide, with primar

Tone
Positive 75/100
Event
Market update
Published
15 Jul 2026 02:42
Source
Investing.com
The Manila Times Direct company coverage

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ORIC Pharmaceuticals has initiated the Himalayas-1 global Phase 3 registrational trial for metastatic castration-resistant prostate cancer (mCRPC), evaluating rinzimetostat in combination with Bayer's NUBEQA® (darolutamide). This trial, supported by a collaboration with Bayer pro

Tone
Positive 73/100
Event
Market update
Published
14 Jul 2026 20:26
Source
The Manila Times
Stock Titan Direct company coverage

Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial

ORIC Pharmaceuticals announced the initiation of its global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), in collaboration with Bayer. Bayer will supply NUBEQA (darolutamide) free of charge for the trial, which will enroll

Tone
Positive 70/100
Event
Macro sensitivity
Published
14 Jul 2026 20:04
Source
Stock Titan
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in ORIC Response

Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting mixed sentiment with a mid-channel oscillation pattern. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights an

Tone
Positive 64/100
Event
Market update
Published
09 Jul 2026 05:41
Source
Stock Traders Daily
Investing.com Direct company coverage

Oric Pharmaceuticals director Heyman sells $3,600 in stock

Richard A. Heyman, a director at Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), sold 300 shares of company stock for $3,600. The transaction was executed on July 6, 2026, under a Rule 10b5-1 trading plan. This sale comes amidst significant analyst upgrades and promising clinical data

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 23:11
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Oric Pharmaceuticals Inc. on July 8th. The brief piece indicates that ORIC experienced a slight increase of 0.32%. The content primarily presents market data and related news.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan

An entity linked to Oric Pharmaceuticals director Richard A. Heyman, RAHD Capital, LLC, sold 300 shares of ORIC common stock at $12.00 per share on July 6, 2

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC

This article provides a financial overview for Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) on TradingView. It specifically highlights the company's forward price-to-sales ratio. The content also lists various features and financial data points available through the TradingView plat

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:09
Source
TradingView
AD HOC NEWS Direct company coverage

ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth

Oric Pharmaceuticals (ORIC) is a clinical-stage biotechnology company concentrating on small-molecule therapies to overcome resistance mechanisms in cancer treatment, a significant challenge in oncology. The company's strategy involves translating preclinical insights into clinic

Tone
Positive 69/100
Event
Market update
Published
07 Jul 2026 15:40
Source
AD HOC NEWS
TradingView Direct company coverage

Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ

This article provides financial information for Oric Pharmaceuticals, Inc. (DUS:4TZ), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, indicating a focus on financial metrics f

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 10:40
Source
TradingView
Stock Titan Direct company coverage

ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan

Oric Pharmaceuticals (NASDAQ: ORIC) filed a Form 144 indicating a proposed sale of 7,000 Common shares through J.P. Morgan Securities LLC. The filing details two stock option exercises, each for 3,500 shares, dated August 25, 2016, and July 6, 2026. This notification provides tra

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:12
Source
Stock Titan
Stock Titan Direct company coverage

[144] Oric Pharmaceuticals, Inc. SEC Filing

Oric Pharmaceuticals, Inc. (ORIC) filed a Form 144 with the SEC, indicating a proposed sale of 6,400 common shares by a filer who acquired them via stock option exercise on July 31, 2015. The shares, valued at $76,800, are expected to be sold on July 6, 2026, through J.P. Morgan

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:12
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC

This page from TradingView provides financial information specifically focusing on the "Price to earnings forward" metric for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It indicates the company's ticker symbol, NASDAQ listing, and highlights specific financial data points related

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 11:11
Source
TradingView
GlobeNewswire Direct company coverage

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, consisting of 44,400 non-qualified stock options and 7,200 restricted stock units. These grants were approved by ORIC's Compensation Committee and serve as a material inducement to employment i

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:39
Source
GlobeNewswire
Stock Titan Direct company coverage

ORIC awards new hires 44,400 stock options and 7,200 RSUs

ORIC Pharmaceuticals (Nasdaq: ORIC) announced inducement equity grants to three new non-executive employees who started in June 2026. The grants, made on July 1, 2026, include 44,400 non-qualified stock options and 7,200 restricted stock units, approved under Nasdaq Rule 5635(c)(

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards several healthcare companies, including Monopar Therapeutics Inc (MNPR), Oric Pharmaceuticals (ORIC), and Tango Therapeutics (TNGX). Analysts from Piper Sandler, Barclays, H.C. Wainwright, and Canaccord Genuity have issue

Tone
Positive 90/100
Event
Market update
Published
01 Jul 2026 04:40
Source
The Globe and Mail
MSN Direct company coverage

Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation

Wedbush has reiterated its "outperform" recommendation for ORIC Pharmaceuticals (ORIC). The article is brief and does not provide further details on the rationale behind this rating.

Tone
Positive 71/100
Event
Analyst action
Published
30 Jun 2026 04:40
Source
MSN
TradingView Direct company coverage

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC

The article provides a financial overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), focusing on its enterprise value to EBITDA forward metric. It details the company's financial data on the TradingView platform, including market performance and other financial indicators. The

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 08:14
Source
TradingView
TradingView Direct company coverage

Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ

This article provides the "Price to book forward" value for Oric Pharmaceuticals, Inc. (FWB:4TZ) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The article also lists various financial and community features available on the Trad

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC

This article focuses on the enterprise value to EBIT forward for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It appears to be a financial data point presented on TradingView, indicating a specific financial metric for the company. The content primarily consists of navigation and bo

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:09
Source
TradingView
Stock Traders Daily Direct company coverage

Behavioral Patterns of ORIC and Institutional Flows

This article analyzes Oric Pharmaceuticals Inc. (NASDAQ: ORIC), identifying strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss l

Tone
Negative 39/100
Event
Guidance
Published
28 Jun 2026 04:40
Source
Stock Traders Daily
TradingView Direct company coverage

Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC)

This article provides key financial data and analyst estimates for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), including current stock price, historical performance, market capitalization, and upcoming earnings dates. It also covers analyst price forecasts, past earnings results, r

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:40
Source
TradingView
Stock Titan Direct company coverage

ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay

ORIC Pharmaceuticals' stockholders have approved an amended 2020 Equity Incentive Plan, which revises the annual share increase and clarifies limits on incentive stock options. The company also announced the election of two Class III directors, ratification of KPMG LLP as auditor

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Stock Titan